




RealRate

PHARMACEUTICAL 2021

VYNE Therapeutics Inc
Rank 364 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of VYNE Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 9.3% points. The greatest weakness of VYNE Therapeutics Inc is the variable Assets, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is 91%, being 165% points below the market average of 256%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	87,259	Assets	93,742
Cost of Goods Sold	1,392	Liabilities	56,249
Intangible Assets	0	Expenses	276,279
Liabilities, Current	21,453	Revenues	20,993
Liabilities, Non-Current	34,796	Stockholders Equity	37,493
Other Assets	5,928	Net Income	-256,396
Other Compr. Net Income	-5.0	Comprehensive Net Income	-256,398
Other Expenses	141,811	BaseVar	224,189
Other Liabilities	0	ECR before LimitedLiability	-233%
Other Net Income	-1,110	Economic Capital Ratio	91%
Other Revenues	20,993		
Property and Equipment	555		
Research and Development	43,533		
Selling, General and Administrative Expense	89,543		